Kawasaki, Japan

Naotoshi Sawada

This inventor holds 3 USPTO granted patents. Top assignee: Kowa Company Limited. Active years: 1983-1984.


% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1983-1984

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Naotoshi Sawada: Innovator in Pharmaceutical Compounds

Introduction

Naotoshi Sawada is a prominent inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceutical compounds, holding a total of 3 patents. His work focuses on innovative chemical compounds that have potential applications in medicine.

Latest Patents

Among his latest patents, Sawada has developed aromatic aminoethanol compounds, which are represented by a specific formula. This compound has potential applications in various therapeutic areas. Additionally, he has patented dihydrobenzopyran compounds, which include a pharmaceutical composition that utilizes a benzopyran compound represented by another specific formula. These innovations highlight his commitment to advancing pharmaceutical science.

Career Highlights

Naotoshi Sawada is associated with Kowa Company Limited, a well-respected organization in the pharmaceutical industry. His work at Kowa has allowed him to focus on the development of novel compounds that can lead to new treatment options for patients.

Collaborations

Throughout his career, Sawada has collaborated with notable colleagues, including Seiichi Sato and Hiromichi Shigyo. These partnerships have contributed to the success of his research and the advancement of his patented technologies.

Conclusion

Naotoshi Sawada's contributions to the field of pharmaceutical compounds demonstrate his innovative spirit and dedication to improving healthcare. His patents reflect a commitment to developing new therapeutic solutions that can benefit society.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…